Hinova Pharmaceuticals Inc. (SHA:688302)

Hinova Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	201.11	633.44	813.23	1,202	901.22	1,139
Trading Asset Securities	581.54	210.49	290.62	366.24	-	-
Cash & Short-Term Investments	782.65	843.93	1,104	1,568	901.22	1,139
Cash Growth	-23.25%	-23.55%	-29.59%	73.97%	-20.85%	4801.37%
Other Receivables	0.66	0.84	1.39	1.67	0.54	0.14
Receivables	0.66	0.84	1.39	1.67	0.54	0.14
Inventory	0.94	0	0.01	0.01	0	0
Prepaid Expenses	-	-	-	-	13.09	-
Other Current Assets	149.86	40.77	41.99	41.78	40.38	43.67
Total Current Assets	934.1	885.54	1,147	1,611	955.24	1,182
Property, Plant & Equipment	334.27	328.62	187.99	86.61	12.72	4.27
Long-Term Investments	7.03	113.09	109.98	5	-	-
Other Intangible Assets	30.34	30.56	31.21	31.86	-	-
Long-Term Deferred Charges	-	-	0.04	0.08	-	0.63
Other Long-Term Assets	4.12	3.77	15.12	0.21	14.39	0.59
Total Assets	1,310	1,362	1,492	1,735	982.35	1,188
Accounts Payable	108.78	40.63	3.14	2.29	1.31	52.66
Accrued Expenses	7.59	31.09	49.17	69.81	90.45	4.93
Short-Term Debt	-	-	-	30	-	0.5
Current Portion of Leases	3.19	3.22	3.77	2.45	2.8	-
Current Income Taxes Payable	0.64	-	-	-	-	0.2
Other Current Liabilities	4.36	72.01	50.76	33.73	96.77	141
Total Current Liabilities	124.55	146.95	106.84	138.27	191.33	199.29
Long-Term Leases	5.09	5.83	9.08	3.31	1.11	-
Long-Term Unearned Revenue	16.55	16.55	8.55	8.1	1.15	2.45
Total Liabilities	146.19	169.33	124.47	149.68	193.59	201.74
Common Stock	99.02	99.02	99.02	99.02	74.26	74.26
Additional Paid-In Capital	2,587	2,583	2,558	2,482	1,409	1,300
Retained Earnings	-1,522	-1,490	-1,290	-996.06	-694.54	-388.36
Comprehensive Income & Other	-0.04	-0.03	0.11	0.14	-0.07	-0.04
Total Common Equity	1,164	1,192	1,367	1,585	788.76	986.15
Shareholders' Equity	1,164	1,192	1,367	1,585	788.76	986.15
Total Liabilities & Equity	1,310	1,362	1,492	1,735	982.35	1,188
Total Debt	8.28	9.05	12.85	35.76	3.91	0.5
Net Cash (Debt)	774.37	834.88	1,091	1,532	897.31	1,138
Net Cash Growth	-23.09%	-23.48%	-28.79%	70.74%	-21.16%	6142.95%
Net Cash Per Share	7.76	8.41	11.02	16.87	12.07	16.19
Filing Date Shares Outstanding	99.02	99.02	99.02	99.02	74.26	74.26
Total Common Shares Outstanding	99.02	99.02	99.02	99.02	74.26	74.26
Working Capital	809.54	738.59	1,040	1,473	763.91	983.11
Book Value Per Share	11.75	12.04	13.81	16.01	10.62	13.28
Tangible Book Value	1,133	1,162	1,336	1,554	788.76	986.15
Tangible Book Value Per Share	11.45	11.73	13.49	15.69	10.62	13.28
Machinery	-	17.15	15.49	14.85	11.16	8.69
Construction In Progress	-	314.5	169.54	73.76	3	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.